Table 2. LDCT findings, cancer characteristics, and pathologic features of participants with and without lung cancer.
| Characteristics | Lung cancer (n=53) | Non-lung cancer (n=4,425) |
|---|---|---|
| LDCT finding | ||
| Pulmonary nodule, LUNG-RADS 1 | – | 1,978 (44.7) |
| Pulmonary nodule, LUNG-RADS 2 | 1 (1.9) | 2,154 (48.7) |
| Pulmonary nodule, LUNG-RADS 3 | 1 (1.9) | 205 (4.6) |
| Pulmonary nodule, LUNG-RADS 4A | 7 (13.2) | 53 (1.2) |
| Pulmonary nodule, LUNG-RADS 4B | 21 (39.6) | 31 (0.7) |
| Pulmonary nodule, LUNG-RADS 4X | 23 (43.4) | 4 (0.1) |
| Positive CT finding (LUNG-RADS 2–4) | 53 (100.0) | 2,447 (55.3) |
| Negative CT finding (LUNG-RADS 1) | – | 1,978 (44.7) |
| Staging | ||
| Stage 0 | 1 (1.9) | |
| Stage IA1 | 4 (7.5) | |
| Stage IA2 | 20 (37.7) | |
| Stage IA3 | 9 (17.0) | |
| Stage IB | 3 (5.7) | |
| Stage IIA | 1 (1.9) | |
| Stage IIB | 2 (3.8) | |
| Stage IIIA | 0 (0.0) | |
| Stage IIIB | 3 (5.7) | |
| Stage IIIC | 0 (0.0) | |
| Stage IVA | 7 (13.2) | |
| Stage IVB | 3 (5.7) | |
| Imaging | ||
| Solid | 41 (77.4) | |
| Part solid | 10 (18.9) | |
| Ground glass | 2 (3.8) | |
| Pathology report | ||
| Adenocarcinoma in situ | 1 (1.9) | |
| Minimally invasive adenocarcinoma | 13 (24.6) | |
| Invasive adenocarcinoma | 31 (58.5) | |
| Squamous cell carcinoma | 4 (7.5) | |
| MALT lymphoma | 1 (1.9) | |
| Small cell carcinoma | 1 (1.9) | |
| Neuroendocrine | 1 (1.9) | |
| Large cell carcinoma | 1 (1.9) | |
| Tumor size, mm | ||
| <6 | 0 (0.0) | |
| 6–8 | 1 (1.9) | |
| >8, ≤15 | 17 (32.1) | |
| >15, ≤30 | 24 (45.3) | |
| >30 | 11 (20.8) |
Data are presented as n (%). CT, computed tomography; LDCT, low-dose computed tomography; LUNG-RADS, Lung Imaging Reporting and Data System; MALT, mucosa-associated lymphoid tissue.